Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Sallmon, H; Hoene, V; Weber, SC; Dame, C.
Differentiation of human SH-SY5Y neuroblastoma cells by all-trans retinoic acid activates the interleukin-18 system.
J Interferon Cytokine Res. 2010; 30(2):55-8
Doi: 10.1089/jir.2009.0036
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Sallmon Hannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The clinical prognosis of children with high-stage neuroblastoma is still poor. Therapeutic approaches include surgery and cellular differentiation by retinoic acid, but also experimental interleukin-based immune modulation. However, the molecular mechanisms of all-trans retinoic acid (ATRA)-induced differentiation of neuroblastoma cells are incompletely understood. Herein, we examined the effect of ATRA on the activity of the interleukin-18 (IL-18) system in human SH-SY5Y neuroblastoma cells. It is shown that SH-SY5Y cells express IL-18 receptor (IL-18R) and the secreted antagonist IL-18-binding protein (IL-18BP), but no IL-18. SH-SY5Y cells are highly sensitive to ATRA treatment and react by cellular differentiation from a neuroblastic toward a more neuronal phenotype. This was associated with induction of IL-18 and reduction of IL-18BP expression, while IL-18R expression remained stable. Thereby, we identified the IL-18 system as a novel target of ATRA in neuroblastoma cells that might contribute to the therapeutic properties of retinoids in treatment of neuroblastoma.
- Find related publications in this database (using NLM MeSH Indexing)
- Cell Differentiation - drug effects
- Cell Line, Tumor - administration & dosage
- Humans - administration & dosage
- Intercellular Signaling Peptides and Proteins - metabolism
- Interleukin-18 - immunology
- Neuroblastoma - immunology, pathology
- Receptors, Interleukin-18 - biosynthesis
- Tretinoin - pharmacology